Objectives: To evaluate possible efficacy of rabbit antithymocyte globulin (RATG) to treat biopsy proven myocarditis. Background: In a murine model, antithymocyte serum improved survival in T-cell and humorally mediated viral myocarditis. RATG, an analogous drug used in human transplantation may have a role in treating myocarditis. Methods: From Jan. 93 to Oct 02, all patients referred with biopsy proven myocarditis, (Dallas Criteria) were given RATG, either locally manufactured (200mg IM) or commercially prepared (Thymoglobuline 1.5 mg/kg IV), for a three-day course and then rebiopsied. Patients with active myocarditis on the repeat biopsy were given a second three-day course and rebiopsied. Adjunctive steroids were given in conjunction with RATG except in two patients on cardiac assist devices where steroids were contraindicated. Echocardiograms (echo) were obtained before RATG, at discharge and last follow-up. Results: Six patients entered the study; all with marked reductions in ejection fraction (EF) by echo. Two patients did not require IV inotropes, two required IV inotropes and two required assist devices and inotropes. All patients had improvement in heart biopsies after RATG but one required a second course. One patient died of multiorgan failure while on an assist device. The five survivors had improvement in EF at the time of discharge over admission EF. Long-term follow-up, (mean 1466 days) showed the EF stayed the same or improved compared to the discharge EF in four patients but decreased in one. Conclusion: RATG may be beneficial in the treatment of myocarditis. RATG causes a profound lymphopenia, inhibits cytokines, blocks co-stimulation molecules and may induce self-tolerance. A multicenter trial is needed to assess efficacy and safety.
Background: Cardiotropic viruses can influence diastolic LV function. In the present study, we report on the association of parvovirus B19 (PVB) genomes in the clinical setting of isolated LV diastolic dysfunction (LVDD). Methods: 33 patients (18 women, 15 men; aged 47±13), presented with exertional dyspnoea, orthopnoea and/or reduced exercise tolerance and preserved systolic function (EF>55%) were included. LVDD was diagnosed when patients showed in addition abnormal transmitral inflow ratio (E/A) (<1, age-related), deceleration time (DT) (>240ms; agerelated), end-diastolic pressure (EDP) (>16 mmHg), and/or wedge pressure (PC) at rest (>12 mmHg) and during exercise (>20 mmHg). We also investigated N-terminal (NT)-proB-type natriuretic peptide (BNP) plasma levels (Elecsys 2010, Roche Diagnostic, Germany) and endothelial dysfunction (ED) by intracoronary injections of ergonovine or acetylcholine. RV myocardial biopsy were taken for entero (EV) -and adenovirus (AV) genome analysis by nested PCR/RT PCR. Patients with coronary artery or valvular disease, LV hypertrophy, hypertension, or lung diseases were excluded. Results: In 27 patients (82%) isolated LVDD was diagnosed. They differed significantly in all Doppler parameters, EDP, stress PC and in increased BNP levels (>10 pmol/l) (P<0.05) compared to patients without LVDD. In 24 out of 27 patients with LVDD (P<0.01) and in 2 of 6 patients without LVDD (n. s.) PVB19, AV and/or EV genomes were detected. With 92% PVB19 was the most frequent pathogen. ED was detected in 18 out of 26 examined patients. 16 patients with ED showed also LVDD. All of these patients were virus-positive (P<0.01). Only in 3 virus-positive patients with LVDD no ED was detected. Conclusion: The genome of the vasculotropic PVB19 can be demonstrated in 89% of patients with isolated LVDD and is strongly associated with the incidence of ED. Thus, PVB19 induced ED-depend ischemia is a possible mechanism to induce LVDD. 10:15 a.m.
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Short Background: Smooth muscle cell (SMC) proliferation is a hallmark of transplant vasculopathy (TV). The goal of this study was to determine the ability of gamma camera imaging of a monoclonal antibody (Z2D3) tagged with Indium-111 to detect TV. Methods: Coronary to right carotid transplantation was performed in 10 Yucatan mini pigs using farm pigs as donors. In 5 of these experiments the RC was also grafted into the LC (homografts) and in one farm pig the LC and RC were switched. After 44±22 days animals were injected with BrdU, underwent planar and SPECT imaging and were sacrificed and vessels removed. Tissue was sectioned and stained. Quantitative morphometry was performed. SMC proliferation index (BrdU-actin cells/actin x 100), was correlated with in vivo and ex vivo uptake. Results: Patency was obtained in only 5/10 allografts and 3/7 homografts. Six of the scans were positive for focal tracer uptake in the neck and 10 were negative. Actin +/ BrdU + cells were seen in the media of allografts and in the recanalized lumen of occluded homografts. A SMC proliferative index of 30% was used as a cut-off for scan poistivity. By chi square there was significant concordance in 14 experiments and discordance in 2 (p=0.008). When ex-vivo vessel counts were correlated with SMC proliferation index there was a significant correlation with r2=0.528 (p<0.01).
Conclusion:
The use of the monoclonal antibody Z2D3 tagged with Indium-111 allows the detection of proliferating SMC and correlates with the intensity of cell proliferation. Background: The routine use of statin therapy has been shown to reduce significantly the risk of developing coronary allograft vasculopathy (CAV) in adult heart transplant recipients. As such, we instituted a practice of routine pravastatin therapy for all pediatric transplant patients regardless of lipid status starting in 1998. Whether statin therapy lowers the risk of developing CAV following heart transplantation in children, however, is not known. Methods: All pediatric patients who had undergone cardiac transplantation at our institution from 1988-2002 were retrospectively reviewed. Pravastatin was administered at doses of 0.2-0.3mg/kg/day. There were 331 person-years of pravastatin treatment. CAV was diagnosed either by coronary angiography or at autopsy. Freedom of CAV was analyzed by Cox-proportional hazards. Results: A total of 129 infants and children underwent 142 heart transplants at a median age of 7.3 yrs. CAV developed in 25 subjects (17.6%). Freedom from CAV was 80% at 5 years. In multivariable analysis use of pravastatin therapy was associated with a significant reduction in CAV (p=0.03). Factors associated with an increased risk of CAV were increased frequency of late rejection and earlier year of transplant (table) . Conclusions: Pravastatin usage is associated with a lower incidence of CAV in pediatric heart transplant recipients. Statin therapy should be considered in the routine maintenance regimen following heart transplantation in children. 
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